| Bioactivity | Perforin-IN-2 is a benzosulfonamide perforin inhibitor that alleviates transplant rejection during allogeneic bone marrow/stem cell transplantation. Perforin-IN-2 binds to plasma proteins with a binding rate of 99.8%. Perforin-IN-2 requires a higher concentration (> 900 μM) to achieve optimal perforin inhibition in vivo. Perforin-in-2 can effectively inhibit the lytic activity of recombinant perforin on Jurkat T (IC50=6.65 μM) leukemia cells, and also inhibit the death of K562 leukemia target cells[1]. |
| Name | Perforin-IN-2 |
| CAS | 1567836-70-7 |
| Formula | C24H18N4O5S2 |
| Molar Mass | 506.55 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Gartlan KH, et al. Preclinical Activity and Pharmacokinetic/Pharmacodynamic Relationship for a Series of Novel Benzenesulfonamide Perforin Inhibitors. ACS Pharmacol Transl Sci. 2022 May 31;5(6):429-439. |
Perforin-IN-2
CAS: 1567836-70-7 F: C24H18N4O5S2 W: 506.55
Perforin-IN-2 is a benzosulfonamide perforin inhibitor that alleviates transplant rejection during allogeneic bone marro
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.